Hematologic Malignancies Stocks
Biopharmaceutical firms in this sector focus on the research, development, and commercialization of therapies targeting cancers of the blood, bone marrow, and lymph nodes, including leukemia, lymphoma, and multiple myeloma.
As of Oct 23, 2026, Hematologic Malignancies has 35 US-listed companies worth $108B combined. The median member moved +2.9% over the past week; ATNM led among the 25 largest at +34.5% and SLBT trailed at -24.8%.
Companies in Hematologic Malignancies
- ONC – BeiGene, Ltd., $43B
- GMAB – Genmab AS, $26.9B
- INCY – Incyte Corporation, $23.7B
- LEGN – Legend Biotech Corp, $3.7B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- AAPG – Ascentage Pharma Group International, $1.4B
- SNDX – Syndax Pharmaceuticals Inc, $1.2B
- KURA – Kura Oncology Inc, $944M
- RIGL – Rigel Pharmaceuticals Inc, $881M
- SLBT – SL Science Holding Limited Ordinary Shares, $869M
- IMMX – Immix Biopharma Inc, $803M
- GERN – Geron Corporation, $771M
- AUTL – Autolus Therapeutics Ltd, $482M
- IPSC – Century Therapeutics Inc, $250M
- KROS – Keros Therapeutics Inc, $222M
- ADCT – ADC Therapeutics SA, $217M
- LYEL – Lyell Immunopharma Inc, $213M
- VRXA – Veraxa Biotech AG Ordinary Shares, $156M
- CRBU – Caribou Biosciences Inc, $50.4M
- PRPO – Precipio Inc, $38.9M
- ATNM – Actinium Pharmaceuticals Inc, $30.6M
- GTBP – GT Biopharma Inc, $14.5M
- TCRX – Tscan Therapeutics Inc, $13.8M
- CLRB – Cellectar Biosciences Inc, $13.1M
- BLRX – BioLineRx Ltd, $11.7M
- KPTI – Karyopharm Therapeutics Inc, $8.8M
- XCUR – Exicure Inc, $7.3M
- SNTI – Senti Biosciences Inc, $7.1M
- MBRX – Moleculin Biotech Inc, $6.3M
- EGRX – Eagle Pharmaceuticals Inc, $3.3M
- CRIS – Curis Inc, $981,914
- CERO – CERo Therapeutics Holdings, Inc. Common Stock, $644,678
- PBLA – Panbela Therapeutics Inc, $14,564
- SYRS – Syros Pharmaceuticals Inc, $10,732
- NEXI – Neximmune Inc, $139